| Filed On | Filing |
|---|---|
| 14 Oct 2026 |
8-K: Other Events
On October 14, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing plans to initiate an open-label extension (“OLE”) of the Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302 for the treatment of amyotr... |
| 05 Oct 2026 |
8-K: Other Events
On October 5, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing full enrollment of the planned one hundred and twenty (120) patients in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating ... |
| 15 Sep 2026 |
8-K: Other Events
On September 15, 2026, Coya Therapeutics, Inc. (the “Company”) issued a press release announcing that the one hundredth (100th) patient has been enrolled in the Company’s ongoing Phase 2/3 ALSTARS Trial (NCT07161999) evaluating COYA 302,... |
| 11 Aug 2026 | 8-K: Results of Operations and Financial Condition |
| 25 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 12 May 2026 | 8-K: Entry into a Material Definitive Agreement |
| 12 May 2026 | 8-K: Results of Operations and Financial Condition; Other Events |
| 02 Apr 2026 | 8-K: Departure/Election of Directors or Officers; Compensation |
| 16 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 30 Jan 2026 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more |
| 20 Jan 2026 | 8-K: Other Events |
| 08 Jan 2026 | 8-K: Other Events |
| 17 Dec 2025 | 8-K: Other Events |
| 12 Nov 2025 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 27 Oct 2025 | 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more |
| 02 Sep 2025 | 8-K: Other Events |
| 12 Aug 2025 | 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 29 Jul 2025 | 8-K: Other Events |
| 01 Jul 2025 | 8-K: Other Events |
| 26 Jun 2025 | 8-K: Submission of Matters to a Vote of Security Holders |
Loading...
